Clinical Trial

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-04-14; most recent amendment 2025-09-26.
Status change: Recruiting → Active, Not Recruiting 2025-09-26
Status change: Active, Not Recruiting → Recruiting 2025-03-31
Status change: Recruiting → Active, Not Recruiting 2024-01-30
Trial Details
NCT Number NCT05831111
Lead Sponsor ModernaTX, Inc.
Conditions Epstein-Barr Virus Infection
Enrollment 482 participants
Start Date 2023-04-05
Primary Completion 2026-10-13 (estimated)
Study Completion 2026-10-13 (estimated)
Updated on ClinicalTrials.gov 2026-08-11